- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06219356
A Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas
April 24, 2024 updated by: Hangzhou GluBio Pharmaceutical Co., Ltd.
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
Study GLB-002-01 is a first-in-human (FIH), phase 1, open-label, dose escalation and expansion clinical study, the purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of GLB-002 monotherapy in participants with relapsed or refractory Non-Hodgkin lymphomas (R/R NHL).
Study Overview
Study Type
Interventional
Enrollment (Estimated)
110
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jing Liu, MD
- Phone Number: 86-18616699599
- Email: Jing.Liu@glubiotx.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100142
- Recruiting
- Beijing Cancer Hospital
-
Contact:
- Yuqing Song, MD
- Phone Number: 86-010-88121122
- Email: songyuqin622@163.com
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510060
- Recruiting
- Sun Yat-sen University Cancer Center
-
Contact:
- Zhiming Li, MD
- Phone Number: 86-020-87343088
- Email: lizhm@sysucc.org.cn
-
-
Henan
-
Zhengzhou, Henan, China, 450003
- Recruiting
- Henan Cancer Hospital
-
Contact:
- Keshu Zhou, MD
- Phone Number: 86-0371-65587320
- Email: drzhouks77@163.com
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330029
- Recruiting
- Jiangxi Cancer Hospital
-
Contact:
- Yuerong Shuang, MD
- Phone Number: 86-0791-88315120
- Email: shuangyr63@163.com
-
-
Shanghai
-
Shanghai, Shanghai, China, 200032
- Not yet recruiting
- Fudan University Shanghai Cancer Center
-
Contact:
- Jian Zhang, MD
- Phone Number: 86-021-64175590
- Email: syner2000@163.com
-
-
Tianjin
-
Tianjin, Tianjin, China, 300020
- Recruiting
- Tianjing Medical University Cancer Institute and Hospital
-
Contact:
- Lihua Qiu, MD
- Phone Number: 86-022-23109106
- Email: JZXQLH@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Participants must understand and voluntarily sign a written informed consent form (ICF) prior to any study-related assessments/procedures being performed.
- Participants is ≥18 years of age at the time of signing the ICF.
- Participants with histopathologically or immunohistochemically confirmed NHL according to 2016 World Health Organization (WHO) haematolymphoid tumors criteria classification (CLL/SLL diagnosis according to 2018 IWCLL) who have failed standard of care therapy or lack an effective treatment regimen.
- Participants in Phase Ib screening period with measurable lesion, but no measurable nodal lesion limit for participants in Phase Ia.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0,1 or 2.
- Life expectancy > 3 months.
- Good performance of major organs, including hematology, liver and kidney function, and coagulation. etc.
- Participants are willing and able to adhere to the study visit schedule and other protocol requirements.
Exclusion Criteria:
- Receipt of anticancer medications/therapies such as chemotherapy, targeted therapy, immunotherapy, biologic therapy, or herbal agent ≤ 28 days or 5 half-lives, whichever is shorter, prior to the first dose of GLB-002; or chimeric antigen receptor T cell therapy (CAR-T) within 3 months prior to the first dose of GLB-002.
- Currently enrolled in any other investigational drug study or participation within the last 28 days or 5 half-lives, whichever is shorter, prior to the first dose of GLB-002 (exception of participants who participated in only one investigational drug study with overall survival follow-up).
- Participants with unresolved clinically significant toxicities of > Grade 1 AE or not be recovered to baseline value from prior anticancer therapies with exception of alopecia or hyperpigmentation of the skin.
- Participants who are scheduled to receive other anticancer therapies or other investigational drugs during the study period.
- Participants with active acute or chronic graft versus host disease (GVHD) requiring systemic immunosuppressive therapy (except corticosteroids at a dose equivalent to 12 mg or less of prednisone per day).
- Receipt of Autologous Stem Cell Transplantation (ASCT) within the last 3 months, or allogeneic hematopoietic stem cell transplantation (allo-HSCT) within the last 6 months prior to the first dose of GLB-002.
- Participants with known active leukemic involvement in central nervous system (CNS).
- Participants with peripheral neuropathy ≥ Grade 2 (Graded according to CTCAE version 5.0).
- History of, or current active cancer other malignancy for the past 5 years, with the exception of curatively resected cancer in situ, including cervical carcinoma in situ, basal cell carcinoma of the skin, or prostate cancer in situ, etc
- QT interval interval >470 milliseconds (ms) using electrocardiographic (ECG) at Screening.
- Participants has impaired cardiac function or clinically significant cardiac disease at current or within last 6 months.
- Participants with known active infection of hepatitis B virus (HBV) or hepatitis C virus C (HCV).
- Participants with known human immunodeficiency virus (HIV) infection.
- Participants with known life-threatening or clinical significant uncontrolled active systemic infections unrelated to malignant hematologic diseases
- Participants with a condition that may affects the absorption, distribution, metabolism and excretion of GLB-002.
- Medications or supplements that are known to be strong and moderate inhibitors or inducers of cytochrome P-450 isozyme (CYP)3A4/5 and/or P-glycoprotein (P-gp) within 7 days or 5 half-lives prior to the first dose of GLB-002, whichever is shorter.
- Participants who have undergone major surgery within 28 days prior to the first dose of the GLB-002.
- Pregnant or lactating women.
- Participants who have cognitive impairment due to any psychiatric or neurological condition, including epilepsy and dementia, may limit their understanding, performance, and study compliance with the ICF.
- Participants,in the opinion of the Investigator, who are unsuitable to participate in the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose Escalation of GLB-002 in Participants with R/R NHL-Phase 1a
Part 1a (Dose Escalation) of the study will enroll R/R NHL participants and will evaluate the safety, tolerability, PK, PD and preliminary efficacy of GLB-002 administered orally, and determine the maximum tolerated dose (MTD) and/or recommended expansion doses (RED) in R/R NHL patients who are eligible for dose limiting toxicity (DLT) evaluation.
|
Administered orally according to the assigned treatment schedule.
Other Names:
|
Experimental: Dose Expansion of GLB-002 in Participants with R/R FL (Grade 1, 2, 3a)-Phase 1b Cohort 1
Part 1b (Dose Expansion) Cohort 1 will confirm tolerability of the selected doses and schedules and evaluate whether efficacy is in a range that warrants further clinical development for R/R Follicular Lymphoma (Grade 1、2、3a).
|
Administered orally according to the assigned treatment schedule.
Other Names:
|
Experimental: Dose Expansion of GLB-002 in Participants with R/R DLBCL and FL (Grade 3b)-Phase 1b Cohort 2
Confirm tolerability of the selected doses and schedules and evaluate whether efficacy is in a range that warrants further clinical development for R/R Diffuse Large B-cell Lymphoma and R/R Follicular Lymphoma (Grade 3b).
|
Administered orally according to the assigned treatment schedule.
Other Names:
|
Experimental: Dose Expansion of GLB-002 in Participants with other R/R NHL-Phase 1b Cohort 3
Part 1b (Dose Expansion) Cohort 3 will confirm tolerability of the selected doses and schedules and evaluate whether efficacy is in a range that warrants further clinical development for other R/R NHL, including, but not limited to Mantle-cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Small Lymphocytic Lymphoma (SLL) /Chronic Lymphocytic Leukemia (CLL) and Peripheral T-cell Lymphoma (PTCL).
|
Administered orally according to the assigned treatment schedule.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose-limiting Toxicity (DLT)
Time Frame: Up to 35 days after first dose of study treatment in Phase 1a
|
DLT is defined as the treatment emergent adverse events (TEAEs) meeting protocol specified DLT criteria and occurring within the DLT assessment period, except those that are clearly and incontrovertibly due to extraneous causes including disease progression, pre-existing medical condition that has not worsened from baseline, or other causes that are clearly not due to study drug.
|
Up to 35 days after first dose of study treatment in Phase 1a
|
Maximum Tolerated Dose (MTD)
Time Frame: Up to 2 years (each cycle is 28 days)
|
MTD is defined as the highest dose level at which no more than 1 of 6 DLT-evaluable participants experienced a DLT.
|
Up to 2 years (each cycle is 28 days)
|
Recommended Expansion Doses (RED)
Time Frame: Up to 2 years (each cycle is 28 days)
|
RED will be decided by safety review committee (SRC) considering the data including safety, tolerability, PK, PD, and preliminary efficacy of GLB-002 in dose escalation.
RED will be the dose level below MTD.
|
Up to 2 years (each cycle is 28 days)
|
Incidence, Relatedness, Seriousness and Severity of Adverse Events (AEs)
Time Frame: Up to 2 years
|
AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.
AE will be graded according to the National Cancer Institute Common Terminology Criteria for AE (NCI CTCAE) version 5.0.
|
Up to 2 years
|
Recommended Phase 2 Dose (RP2D)
Time Frame: Up to 2 years
|
RP2D based on the totality of data across dosing cohorts in the dose escalation and expansion phases of the study including PK, PD, safety and efficacy outcomes.
|
Up to 2 years
|
Objective Response Rate (ORR)
Time Frame: Up to 2 years
|
ORR is defined as the percent of participants whose best overall response is complete response (CR) or partial response (PR).
CR and PR will be assessed by 2014 Lugano for NHL and/or 2018 International Working Group Criteria for Chronic Lymphocyte Leukemia (2018 IWCLL).
|
Up to 2 years
|
Time to Response (TTR)
Time Frame: Up to 2 years
|
For participants with objective response, TTR was defined as the time of participants from the first treatment administration to the first incidence of a confirmed CR or PR was reported.
CR and PR will be assessed by 2014 Lugano for NHL and/or 2018 IWCLL.
|
Up to 2 years
|
Duration of Remission or Response (DOR)
Time Frame: Up to 2 years
|
For participants with objective response, DOR is measured from the time of any of CR or PR are first met (whichever is first recorded) until the first date at which progressive disease or death from any cause is objectively documented assessment.
CR and PR will be assessed by 2014 Lugano for NHL and/or 2018 IWCLL.
|
Up to 2 years
|
Progression-free Survival (PFS)
Time Frame: Up to 2 years
|
PFS is defined as the time from the first dose of GLB-002 to the first occurrence of progressive disease (PD) or death from any cause.
PD will be assessed by 2014 Lugano for NHL and/or 2018 IWCLL.
|
Up to 2 years
|
Overall Survival (OS)
Time Frame: Up to 2 years
|
OS is defined as the time from the first dose of GLB-002 to death due to any cause.
|
Up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
GLB-002 and GLB-A062-A (R-enantiomers of GLB-002) Pharmacokinetics after Single Administration-AUC0-last
Time Frame: Up to 48 hours after single administration
|
Area under the concentration-time curve from zero to the last measurable concentration
|
Up to 48 hours after single administration
|
GLB-002 and GLB-A062-A Pharmacokinetics after Single Administration-AUC0-24
Time Frame: Up to 48 hours after single administration
|
Area under the concentration-time curve from 0 to 24 hours
|
Up to 48 hours after single administration
|
GLB-002 and GLB-A062-A Pharmacokinetics after Single Administration-AUC0-inf
Time Frame: Up to 48 hours after single administration
|
Area under the concentration-time curve from 0 to infinity
|
Up to 48 hours after single administration
|
GLB-002 and GLB-A062-A Pharmacokinetics after Single Administration-Cmax
Time Frame: Up to 48 hours after single administration
|
Maximum plasma concentration
|
Up to 48 hours after single administration
|
GLB-002 and GLB-A062-A Pharmacokinetics after Single Administration-Tmax
Time Frame: Up to 48 hours after single administration
|
The time to reach maximum concentration
|
Up to 48 hours after single administration
|
GLB-002 and GLB-A062-A Pharmacokinetics after Single Administration-T1/2
Time Frame: Up to 48 hours after single administration
|
Terminal half-life
|
Up to 48 hours after single administration
|
GLB-002 and GLB-A062-A Pharmacokinetics after Single Administration-Vz/F
Time Frame: Up to 48 hours after single administration
|
Apparent volume of distribution
|
Up to 48 hours after single administration
|
GLB-002 and GLB-A062-A Pharmacokinetics after Single Administration-CL/F
Time Frame: Up to 48 hours after single administration
|
Apparent total clearance of the drug from plasma after oral administration
|
Up to 48 hours after single administration
|
GLB-002 and GLB-A062-A Pharmacokinetics after Single Administration-λz
Time Frame: Up to 48 hours after single administration
|
Terminal rate constant
|
Up to 48 hours after single administration
|
GLB-002 and GLB-A062-A Pharmacokinetics after Multiple Administration-Tmax,SS
Time Frame: Up to 2 years
|
Time of maximum concentration at steady state
|
Up to 2 years
|
GLB-002 and GLB-A062-A Pharmacokinetics after Multiple Administration-Cav,SS
Time Frame: Up to 2 years
|
Average plasma concentration at steady state
|
Up to 2 years
|
GLB-002 and GLB-A062-A Pharmacokinetics after Multiple Administration-Cmax,SS
Time Frame: Up to 2 years
|
Maximum plasma concentration at steady state
|
Up to 2 years
|
GLB-002 and GLB-A062-A Pharmacokinetics after Multiple Administration-Cmin,SS
Time Frame: Up to 2 years
|
Minimum plasma concentration at steady state
|
Up to 2 years
|
GLB-002 and GLB-A062-A Pharmacokinetics after Multiple Administration-AUC0-tau
Time Frame: Up to 2 years
|
Area under the concentration-time curve during the dosing interval
|
Up to 2 years
|
GLB-002 and GLB-A062-A Pharmacokinetics after Multiple Administration-λz
Time Frame: Up to 2 years
|
Terminal rate constant
|
Up to 2 years
|
GLB-002 and GLB-A062-A Pharmacokinetics after Multiple Administration-Vz/F
Time Frame: Up to 2 years
|
Apparent volume of distribution
|
Up to 2 years
|
GLB-002 and GLB-A062-A Pharmacokinetics after Multiple Administration-CLSS/F
Time Frame: Up to 2 years
|
Apparent clearance at steady state
|
Up to 2 years
|
GLB-002 and GLB-A062-A Pharmacokinetics after Multiple Administration-T1/2
Time Frame: Up to 2 years
|
Terminal half-life
|
Up to 2 years
|
GLB-002 and GLB-A062-A Pharmacokinetics after Multiple Administration-Rac [AUC]
Time Frame: Up to 2 years
|
Accumulation index in area under the concentration-time curve
|
Up to 2 years
|
GLB-002 and GLB-A062-A Pharmacokinetics after Multiple Administration-Rac [Cmax]
Time Frame: Up to 2 years
|
Accumulation index in maximum plasma concentration
|
Up to 2 years
|
GLB-002 and GLB-A062-A Pharmacokinetics after Multiple Administration-DF
Time Frame: Up to 2 years
|
Degree of fluctuation index
|
Up to 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Gang Lu, Ph.D., Hangzhou GluBio Pharmaceutical Co., Ltd.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 11, 2024
Primary Completion (Estimated)
January 31, 2026
Study Completion (Estimated)
February 28, 2027
Study Registration Dates
First Submitted
December 22, 2023
First Submitted That Met QC Criteria
January 12, 2024
First Posted (Actual)
January 23, 2024
Study Record Updates
Last Update Posted (Actual)
April 26, 2024
Last Update Submitted That Met QC Criteria
April 24, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GLB-002-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-Hodgkin Lymphoma
-
Caribou Biosciences, Inc.RecruitingLymphoma | Lymphoma, Non-Hodgkin | B Cell Lymphoma | Non Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma | B Cell Non-Hodgkin's LymphomaUnited States, Australia, Israel
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin LymphomaUnited States
-
Marker Therapeutics, Inc.RecruitingNon Hodgkin Lymphoma | Non-Hodgkin Lymphoma, Adult | Non-Hodgkin Lymphoma, Refractory | Non-Hodgkin Lymphoma, RelapsedUnited States
-
National Cancer Institute (NCI)RecruitingRefractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Recurrent Primary Cutaneous... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRefractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Hematopoietic Cell Transplantation RecipientUnited States
-
Mayo ClinicNot yet recruitingIndolent B-Cell Non-Hodgkin Lymphoma | Recurrent Indolent Non-Hodgkin Lymphoma | Refractory Indolent Non-Hodgkin Lymphoma | Recurrent Indolent B-Cell Non-Hodgkin Lymphoma | Refractory Indolent B-Cell Non-Hodgkin LymphomaUnited States
-
University of WashingtonRecruitingRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin LymphomaUnited States
-
Chongqing Precision Biotech Co., LtdRecruitingNon Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Relapsed Non-Hodgkin LymphomaChina
-
Estrella Biopharma, Inc.Eureka Therapeutics Inc.Not yet recruitingLymphoma | Lymphoma, Non-Hodgkin | Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | CNS Lymphoma | Lymphomas Non-Hodgkin's B-Cell | Relapsed Non-Hodgkin Lymphoma | Lymphoma, Non-Hodgkins | Large B-Cell Lymphoma and other conditions
Clinical Trials on GLB-002
-
GluBio Therapeutics Inc.RecruitingAcute Myeloid Leukemia | Myelodysplastic SyndromesUnited States
-
University of PittsburghUnited States Department of DefenseCompletedMetabolic Syndrome | PrediabetesUnited States
-
Ohio State UniversityCompleted
-
Hangzhou GluBio Pharmaceutical Co., Ltd.Not yet recruitingAcute Myeloid Leukemia | Myelodysplastic Syndromes | Polycythemia Vera | Essential Thrombocythemia | Myelofibrosis | Myeloid MalignancyChina
-
Lovoria WilliamsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Recruiting
-
University of PittsburghCompletedQuality of Life | Obesity | Physical Activity | Diet Modification | Cardiovascular Risk Factor | Mobility Limitation | Eating Behavior
-
University of PittsburghRobert C. Atkins FoundationCompleted
-
Baylor Research InstituteActive, not recruitingObesity | Weight Loss | Diet Modification | Spinal Cord InjuriesUnited States
-
Baylor Research InstituteActive, not recruitingHypertension | Risk Reduction Behavior | African Americans | Diet, Carbohydrate-RestrictedUnited States
-
Avalo Therapeutics, Inc.CompletedNon-Eosinophilic AsthmaUnited States